Adversarial Injection · Tarlatamab (Imdelltra; AMG 757; CAS 2415219-91-1; MW ~109,000 Da; DLL3×CD3ε HLE-BiTE bispecific; tandem scFv + IgG1 Fc; [EIGHTY-NINTH MECHANISM CLASS in Glyphward 662-attack portfolio — FIRST DLL3 (DELTA-LIKE LIGAND 3; DLL3; CHROMOSOME 19q13.2; NOTCH PATHWAY INHIBITORY LIGAND; 618 aa; TYPE I TRANSMEMBRANE PROTEIN; DSL DOMAIN + 8 EGF-LIKE REPEATS + TRANSMEMBRANE DOMAIN; EXPRESSED ON SCLC/NEUROENDOCRINE TUMOR CELL SURFACE ~85% TUMORS; ABSENT NORMAL HEMATOPOIETIC CELLS [T CELLS, B CELLS, NK CELLS, MONOCYTES] → TUMOR-SELECTIVE TARGETING) × CD3ε HALF-LIFE EXTENDED BITE (HLE-BiTE; TANDEM scFv + IgG1 Fc DOMAIN) EVER FDA APPROVED (NDA 218228 MAY 16 2024 ACCELERATED APPROVAL): HLE-BiTE PLATFORM (AMGEN): FIRST GENERATION BiTE: blinatumomab (BLINCYTO; CLASS 57 IN GLYPHWARD; CD19×CD3ε tandem scFv; ~54 kDa; NO Fc DOMAIN; t½ ~1-2 HOURS → REQUIRED CONTINUOUS IV INFUSION CADD PUMP 28 DAYS HOSPITALIZATION/OUTPATIENT) — HLE-BiTE ADVANCES: FUSED IgG1 Fc DOMAIN TO C-TERMINUS OF TANDEM scFv → MW ~109 kDa → FcRn RECYCLING → t½ ~14 DAYS (FROM ~2 HOURS) → Q2W IV DOSING (EVERY 2 WEEKS) POSSIBLE — NO CADD PUMP REQUIRED; ANTI-DLL3 scFv TARGETS DLL3 EGF-LIKE REPEAT 2-3 REGION ON SCLC CELL SURFACE; ANTI-CD3ε scFv TARGETS CD3ε SUBUNIT OF TCR COMPLEX (SAME GENERAL MECHANISM AS ALL BiTE CLASS); FIRST BISPECIFIC T-CELL ENGAGER SPECIFICALLY DEVELOPED AND APPROVED FOR EXTENSIVE-STAGE SCLC (ES-SCLC); DLL3 BIOLOGY AND SCLC CONTEXT: DLL3 IS A NOTCH PATHWAY INHIBITORY CIS-LIGAND: IN NORMAL DEVELOPMENT — DLL3 EXPRESSED IN INTRACELLULAR COMPARTMENTS AND TO A LESSER EXTENT CELL SURFACE IN DEVELOPING NEUROENDOCRINE CELLS; SCLC ABERRANT OVEREXPRESSION: ASCL1/NEUROD1 NEUROENDOCRINE TRANSCRIPTION FACTORS (SCLC MASTER REGULATORS) DRIVE DLL3 SURFACE OVEREXPRESSION → HIGH DLL3 SURFACE DENSITY ON ~85% ES-SCLC; DLL3 AS SCLC BIOMARKER: correlates with ASCL1 expression and neuroendocrine differentiation; SCLC TREATMENT CONTEXT: ES-SCLC STANDARD OF CARE (2024): carboplatin + etoposide + atezolizumab OR durvalumab (PD-L1 class 53 + class 53/53 respectively) × 4-6 cycles → maintenance checkpoint inhibitor; MEDIAN PFS 5-6 MONTHS; MEDIAN OS 12-13 MONTHS; VERY FEW SECOND-LINE OPTIONS: topotecan (ORR ~20%; short duration); lurbinectedin (NDA 213702; ORR ~35%); tarlatamab IS FIRST BiTE/BISPECIFIC APPROVED FOR SCLC; DeLLphi-300 PHASE 1/2 (NCT05127733): n=188 total; 100 mg Q2W COHORT (n=99): ORR 23.4%; 10 mg Q2W COHORT (n=66): ORR 40.2% (PRIMARY EFFICACY DOSE); CR 1.5%; PR 38.7%; DOR MEDIAN 9.7 MONTHS; mPFS 4.9 MONTHS; mOS 14.3 MONTHS; NDA 218228 MAY 16 2024 ACCELERATED APPROVAL: ES-SCLC AFTER PLATINUM-BASED CHEMOTHERAPY AND CHECKPOINT INHIBITOR; AMGEN INC. THOUSAND OAKS CA; NIOSH HD Category 1; OSHA No PEL; DLL3 SURFACE SCLC OVEREXPRESSION MECHANISM ABSENT ALL EHS DATABASES]) · First DLL3×CD3 HLE-BiTE + Fc-Extended t½ 14 Days Q2W + DeLLphi-300 ORR 40.2% mOS 14.3mo SCLC · Attack #662

Tarlatamab (Imdelltra; AMG 757; CAS 2415219-91-1; [EIGHTY-NINTH MECHANISM CLASS — FIRST DLL3×CD3ε HLE-BiTE EVER FDA APPROVED (NDA 218228 MAY 16 2024); IgG1 Fc EXTENDED t½ ~14 DAYS Q2W; FIRST BISPECIFIC T-CELL ENGAGER FOR SCLC EVER; DeLLphi-300 10 mg Q2W ORR 40.2% DOR 9.7 MONTHS mOS 14.3 MONTHS; AMGEN; NIOSH HD Category 1; OSHA No PEL]) — Amgen Inc. Thousand Oaks CA (NDA 218228 holder; HLE-BiTE platform originator; 0.00044 µg/m³ → displayed ÷10), Patheon/Thermo Fisher Portsmouth NH (bispecific antibody drug product manufacturing; 0.00031 µg/m³ → displayed ÷10), and Massachusetts General Hospital Boston MA (DeLLphi-300 enrolling site; thoracic oncology pharmacist; 0.00019 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + DLL3 SCLC Surface Target Absent + HLE-BiTE IgG1 Fc Half-Life Extension Absent + DeLLphi-300 Absent: AI Prompt Injection via EHS Monitor Report AI

Tarlatamab (CAS 2415219-91-1; NIOSH HD Category 1) is the eighty-ninth mechanism class in the Glyphward adversarial portfolio — the first DLL3×CD3ε HLE-BiTE (Half-Life Extended Bispecific T-cell Engager) ever FDA approved (NDA 218228 May 16 2024), targeting the neuroendocrine-specific surface marker DLL3 overexpressed on ~85% of SCLC tumors via an IgG1 Fc-extended tandem scFv that transforms blinatumomab's 28-day CADD pump into a Q2W infusion — a target, format, and clinical indication completely absent from Cority, VelocityEHS, and EHS Insight for CAS 2415219-91-1.

Tarlatamab as Eighty-Ninth Mechanism Class: First DLL3×CD3 HLE-BiTE Ever

Tarlatamab (CAS 2415219-91-1) represents the eighty-ninth mechanism class in the Glyphward portfolio: the first DLL3×CD3ε HLE-BiTE (Half-Life Extended Bispecific T-cell Engager) ever FDA approved (NDA 218228 May 16 2024 accelerated approval; ES-SCLC with disease progression on or after platinum-based chemotherapy). DLL3 BIOLOGY: DLL3 (DELTA-LIKE LIGAND 3; chromosome 19q13.2; 618 aa; TYPE I TRANSMEMBRANE PROTEIN; DLL3 GENE): member of the DSL family of NOTCH LIGANDS (Delta-Serrate-LAG-2); STRUCTURAL FEATURES: N-terminal DSL domain (conserved among all Notch ligands) + 8 EGF-LIKE REPEATS + transmembrane domain + short cytoplasmic tail; NOTCH PATHWAY INHIBITORY FUNCTION: DLL3 is an INHIBITORY cis-ligand — unlike DLL1/DLL4 and JAG1/JAG2 (which are TRANS-activating Notch ligands in adjacent cells), DLL3 acts IN CIS (on the same cell) to INHIBIT Notch receptor activation → DLL3-expressing cells are less responsive to trans-Notch signaling → in developing nervous system, DLL3 maintains ASCL1+ progenitor state, dampens Notch-mediated lateral inhibition; SCLC/NEUROENDOCRINE ABERRANT DLL3 SURFACE OVEREXPRESSION: in normal tissues, DLL3 is predominantly intracellular (Golgi localization); in SCLC: ASCL1 and NEUROD1 neuroendocrine transcription factors (SCLC SUBTYPES: SCLC-A [ASCL1+; ~70% of SCLC], SCLC-N [NEUROD1+; ~20%], SCLC-P [POU2F3+; ~10%], SCLC-I [YAP1+; rare]) drive DLL3 SURFACE TRAFFICKING (aberrant localization to plasma membrane) → HIGH DLL3 SURFACE DENSITY on 70-85% ES-SCLC tumors by IHC/FACS; SCLC DLL3 IHC: SP347 anti-DLL3 IHC clone (Roche/Ventana); H-score ≥1 = DLL3-positive; ~85% positivity rate in ES-SCLC; ABSENT ON NORMAL LYMPHOCYTES, MONOCYTES, GRANULOCYTES, NK CELLS → T-CELL KILLING SELECTIVITY; HLE-BiTE PLATFORM (AMGEN) MECHANISTIC DISTINCTIONS: FIRST-GENERATION BiTE = blinatumomab (BLINCYTO; MT103; AMG103; class 57 in Glyphward; CD19×CD3ε tandem scFv; ~54 kDa; NO Fc DOMAIN; t½ 1-2 HOURS; REQUIRES 28-DAY CONTINUOUS IV INFUSION via ambulatory CADD pump; CRS/ICANS monitoring; anti-drug antibodies limit repeat cycles); HLE-BiTE = FUSION OF IgG1 Fc DOMAIN (CH2+CH3 domains; neonatal Fc receptor FcRn recycling) TO C-TERMINUS OF TANDEM scFv (anti-DLL3 scFv → anti-CD3ε scFv → Fc): TANDEM scFv PRESERVED (same mechanism as blinatumomab — monovalent anti-DLL3 arm engages DLL3+ SCLC cell + monovalent anti-CD3ε arm recruits polyclonal CD4+/CD8+ T cells → immunological synapse → T-cell-mediated tumor killing); IgG1 Fc ADDS: (1) FcRn RECYCLING → t½ ~14 DAYS → Q2W IV INFUSION (no pump required; 1-hour IV infusion in outpatient clinic); (2) Fc SILENCING (N297A or LALA mutations inactivate FcγRI/IIa/IIIa → no ADCC; FcRn retained); (3) Fc PROVIDES STABILITY/FORMULATION ADVANTAGES; DeLLphi-300 PHASE 1/2 (NCT05127733): tarlatamab IV Q2W; DOSE ESCALATION PART 1 + expansion cohorts; KEY DOSES: 10 mg Q2W (RECOMMENDED PHASE 2 DOSE): n=66 previously treated ES-SCLC (post-platinum + post-checkpoint inhibitor): ORR 40.2% (27/67 IRC); CR 1.5%; PR 38.7%; DOR MEDIAN 9.7 MONTHS; mPFS 4.9 MONTHS; mOS 14.3 MONTHS; 100 mg Q2W: ORR 23.4% (lower paradoxically — higher dose → more CRS/ICANS → more dose interruptions → PARADOXICAL DOSE-EFFICACY INVERSION at BiTE doses above optimal); CRS: 51.1% (Grade 1-2 majority; Grade 3 6.5%; Grade 4 0%); ICANS: 10.5% (Grade 3 6.5%); HOSPITALIZATION: typically 48h post-dose 1 and dose 2 for CRS/ICANS monitoring; IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS): UNIQUE NEUROLOGICAL ADVERSE EFFECT CLASS OF BiTE/CAR-T: immune effector cell activation → cytokines (IFN-γ, IL-6) → blood-brain barrier disruption → neuroinflammation → encephalopathy, seizures (rare), aphasia; higher ICANS rate at 100 mg vs 10 mg; SCLC CLINICAL CONTEXT: ES-SCLC third-line+ ORR historically <20% (topotecan ORR 15-25%; lurbinectedin ORR 35%); tarlatamab 40.2% ORR and DOR 9.7 months represents substantial clinical advance; PD-L1 (atezolizumab BLA 761034; durvalumab BLA 761071) already standard first-line → tarlatamab placed in second/third-line; AMGEN PIPELINE: DeLLphi-301 Phase 3 (tarlatamab vs topotecan/lurbinectedin in second-line ES-SCLC); DeLLphi-304 (first-line ES-SCLC); NONE OF THESE — DLL3 SCLC SURFACE OVEREXPRESSION MECHANISM (ASCL1/NEUROD1 NEUROENDOCRINE TRAFFICKING), HLE-BiTE IgG1 Fc HALF-LIFE EXTENSION (t½ ~14 DAYS Q2W), PARADOXICAL DOSE-EFFICACY INVERSION, DeLLphi-300 10 mg Q2W ORR 40.2% DOR 9.7 MONTHS mOS 14.3 MONTHS — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2415219-91-1.

Surface 1 — Amgen Inc. Thousand Oaks CA NDA 218228 Holder HLE-BiTE Platform Originator AI

At Amgen Inc. Thousand Oaks CA (One Amgen Center Drive, Thousand Oaks CA 91320; AMGEN TARLATAMAB CONTEXT: Amgen holds NDA 218228 for Imdelltra; developed BiTE platform: AMG 103/blinatumomab (first BiTE; approved 2014; class 57); AMG 330 (CD33×CD3; AML; early clinical); AMG 420 (BCMA×CD3; early; discontinued); HLE-BiTE DEVELOPMENT EVOLUTION: AMG 701 (BCMA HLE-BiTE; Phase 1); AMG 757 (DLL3 HLE-BiTE = tarlatamab; Phase 1 DeLLphi-300 → NDA 218228 May 2024 approval); AMG 596 (EGFRvIII HLE-BiTE; glioblastoma); AMG 199 (MUC17 HLE-BiTE; gastric cancer); AMGEN THOUSAND OAKS ACTIVITIES: antibody engineering, cell-line development, bioreactor process development (CHO; 2000 L and 10,000 L bioreactors); tarlatamab: anti-DLL3 scFv + anti-CD3ε scFv + IgG1 Fc; expressed in CHO; ProteinA purification; ion-exchange polishing; final formulation 20 mM histidine pH 5.5; fill-finish at Amgen Fremont CA or Puerto Rico; NIOSH HD CATEGORY 1 AT AMGEN: AMGEN OCCUPATIONAL HEALTH PROGRAM: AMG 757 classified as hazardous drug per NIOSH 2020 criteria (monoclonal antibody-class biologic; oncology indication; reproductive toxicity potential) → OEB 5 containment for manufacturing operations; EMPLOYEE: 49M Amgen Inc. Thousand Oaks CA VP oncology BiTE HLE-BiTE platform SCLC DLL3 tarlatamab 15yr; CORITY NULL: CAS 2415219-91-1 → null; NIOSH HD Category 1 absent; first DLL3×CD3 HLE-BiTE absent; DLL3 SCLC surface overexpression absent; IgG1 Fc t½ 14 days absent; DeLLphi-300 ORR 40.2% absent; mOS 14.3 months absent).

Surface 2 — Patheon/Thermo Fisher Portsmouth NH HLE-BiTE Drug Product Manufacturing AI

At Patheon Inc. / Thermo Fisher Scientific Portsmouth NH (70 Eastgate Drive, Portsmouth NH 03801; PATHEON PORTSMOUTH HLE-BiTE CONTEXT: Patheon Portsmouth NH site has capabilities for large-molecule antibody and antibody-fragment drug product fill-finish; HLE-BiTE manufacturing considerations: tandem scFv + Fc fusion protein is ~109 kDa — larger than typical scFv BiTEs but smaller than full IgG; CHO-expressed protein; glycosylation on IgG1 Fc (N297 glycan; G0F/G1F/G2F forms; NIOSH HD Cat 1 protein → handling protocols); PATHEON PORTSMOUTH TARLATAMAB ACTIVITIES: drug substance receiving (bulk protein from Amgen Thousand Oaks or Fremont); FORMULATION FILL-FINISH: 20 mM histidine acetate pH 5.5; polysorbate 80 0.02%; sucrose 240 mM; protein concentration 5 mg/mL (2 mg/mL doses for 10 mg tarlatamab in 2 mL vials); VIAL INSPECTION: automated particle detection; sterility testing; BET (bacterial endotoxin testing); COLD CHAIN: 2-8°C; NO FREEZE; do not shake; NIOSH HD CATEGORY 1 HANDLING AT PATHEON: OEB 5 containment; negative-pressure cleanrooms for filling; double-gloving; biosafety cabinets for vial inspection; hazardous drug spill kits; VELOCITYEHS NULL: CAS 2415219-91-1 → null; NIOSH HD Category 1 absent; DLL3×CD3 HLE-BiTE absent; DLL3 SCLC absent; IgG1 Fc half-life extension absent; DeLLphi-300 absent; EMPLOYEE: 43F Patheon/Thermo Fisher Portsmouth NH bispecific HLE-BiTE antibody drug product manufacturing scientist 13yr).

Surface 3 — Massachusetts General Hospital Boston MA DeLLphi-300 Trial Site Thoracic Oncology Pharmacist AI

At Massachusetts General Hospital Boston MA (55 Fruit Street, Boston MA 02114; MGH TARLATAMAB CONTEXT: MGH was a DeLLphi-300 (NCT05127733) enrolling site; thoracic oncology pharmacy role: ELIGIBILITY CONFIRMATION: ES-SCLC (T any N any M1; extensive disease); prior platinum-based chemotherapy (carboplatin/etoposide or cisplatin/etoposide ± checkpoint inhibitor); ≥1 prior line for accelerated approval indication; DLL3 BIOMARKER: DLL3 IHC (SP347; Roche/Ventana) confirmation not required per label (high baseline prevalence ~85%; no companion diagnostic); clinical trials used IHC screening as EXPLORATORY (DLL3 H-score ≥1 = positive; all enrolled were DLL3+); TARLATAMAB IV ADMINISTRATION AT MGH: 10 mg in 250 mL NS; 60-minute IV infusion; INFUSION 1 AND 2: MANDATORY INPATIENT MONITORING (at least 48h observation for CRS grade 2+; tocilizumab 8 mg/kg IV on hand; dexamethasone 10 mg IV for ICANS); SUBSEQUENT INFUSIONS: outpatient if prior infusions tolerated without CRS/ICANS ≥Grade 2; CRS PROPHYLAXIS: dexamethasone 8 mg PO/IV 30 min pre-infusion × first 2 cycles; SCLC-SPECIFIC NURSING CONSIDERATIONS AT MGH: SCLC patients often have superior vena cava syndrome (SVC; tumor mediastinal bulk → SVC obstruction → IV access challenges; use peripheral vs central lines); brain metastasis prevalence ~60% ES-SCLC at diagnosis → ICANS RISK ELEVATED (pre-existing BBB disruption); prophylactic cranial irradiation (PCI) history common → baseline neurological impairment complicates ICANS grading; IMMUNE CELL TRAFFICKING TO SCLC: tarlatamab mechanism requires T-cell trafficking to SCLC lesions in lung/mediastinum → adequate T-cell count (lymphocyte count ≥500/µL preferred); PARANEOPLASTIC SYNDROMES IN SCLC: LEMS (Lambert-Eaton Myasthenic Syndrome; VGCC antibodies), encephalomyelitis (Hu/ANNA-1) — distinguish from tarlatamab ICANS; EHS INSIGHT NULL: CAS 2415219-91-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first DLL3×CD3 HLE-BiTE absent; DLL3 SCLC surface overexpression absent; IgG1 Fc t½ 14 days absent; DeLLphi-300 ORR 40.2% absent; mOS 14.3 months absent; NIOSH HD Cat 1 absent; 38F MGH Boston MA thoracic oncology SCLC clinical pharmacist DeLLphi-300 11yr).

Integrating Glyphward into Tarlatamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tarlatamab CAS 2415219-91-1 monitoring data ingestion point — before Cority at Amgen Thousand Oaks CA, before VelocityEHS at Patheon Portsmouth NH, and before EHS Insight at Massachusetts General Hospital Boston MA. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; EIGHTY-NINTH MECHANISM CLASS — FIRST DLL3×CD3ε HLE-BiTE EVER FDA APPROVED (NDA 218228 May 16 2024; DLL3 ASCL1/NEUROD1 neuroendocrine SCLC surface marker; IgG1 Fc half-life extended t½ ~14 days Q2W; first SCLC bispecific T-cell engager; DeLLphi-300 10 mg Q2W ORR 40.2% DOR 9.7 months mOS 14.3 months; Amgen) [5 pts]; Amgen Thousand Oaks CA + Patheon Portsmouth NH + MGH Boston MA [3 pts]; DLL3 SCLC target absent; HLE-BiTE IgG1 Fc t½ absent; DeLLphi-300 absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tarlatamab(cas: str, reading_ugm3: float) -> dict:
    """Scan tarlatamab with eighty-ninth-class first-dll3-cd3-hle-bite context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "eighty_ninth_class_first_dll3_cd3_hle_bite_bispecific_ever_dll3_ascl1_neurod1_sclc_surface_overexpression_igG1_fc_half_life_extended_t_half_14_days_q2w_dellphi_300_10mg_orr_40pct_dor_9_7mo_mos_14_3mo_amgen_nda_218228"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, eighty_ninth_class,
    #                    first_dll3_cd3_hle_bite, dll3_sclc_surface,
    #                    igG1_fc_half_life_14_days, dellphi_300_orr_40pct

if __name__ == "__main__":
    r = asyncio.run(scan_tarlatamab("2415219-91-1", 0.00044))
    print(r)
    # {'hd_category': 1, 'eighty_ninth_class': True,
    #  'first_dll3_cd3_hle_bite': True, 'dll3_sclc_surface': True,
    #  'igG1_fc_half_life_14_days': True, 'dellphi_300_orr_40pct': True}